NCT06627647 2026-02-12A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCAstraZenecaPhase 3 Recruiting878 enrolled
NCT07178795 2025-11-17A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCSichuan Baili Pharmaceutical Co., Ltd.Phase 3 Recruiting440 enrolled